Mutations of the FMS-like tyrosine kinase 3 (FLT3) and DNA methyltransferase 3A (DNMT3A) genes were identified as common driver mutations associated with poor prognosis of AML patients [59]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.